围产期硫酸镁与产后抑郁症状减轻相关
这项前瞻性队列研究纳入342名≥34周妊娠的高血压疾病单胎孕妇,39%(134人)接受围产期硫酸镁预防子痫。与未用镁者相比,用镁者产后2周抑郁症状评分变化更小(0.6±3.4 vs 1.6±3.0;P=.015),评分升高比例更低(52% vs 67%;P=.022);校正混杂后2周评分升高风险仍较低(aOR 0.88;95%CI 0.78-0.98),6周时差异消失。
要点
- 用镁者产后2周抑郁评分升高比例更低(52% vs 67%;P=.022)
- 校正后2周评分升高风险仍较低(aOR 0.88;95%CI 0.78-0.98)
- 产后6周时两组差异不再存在
核心结论
- 围产期硫酸镁与产后早期抑郁症状加重程度较轻相关。
- 产后6周时两组抑郁症状变化无差异。
- 建议开展随机试验验证硫酸镁作为产后抑郁预防措施的潜力。
研究设计与样本
- 前瞻性队列研究,纳入≥34周妊娠的高血压疾病单胎孕妇342例。
- 硫酸镁用于预防子痫由产科医生酌情决定,39%(134例)接受硫酸镁。
- 出院前及产后2周、6周使用Quick Inventory of Depressive Symptomatology问卷评估抑郁症状。
主要发现
- 产后2周抑郁评分平均变化:用镁组0.6±3.4,未用镁组1.6±3.0(P=.015)。
- 产后2周评分升高比例:用镁组52%,未用镁组67%(P=.022)。
- 校正混杂因素后,用镁组产后2周评分升高的校正OR为0.88(95%CI 0.78-0.98)。
- 产后6周时上述差异均不存在。
关键数值与推荐
- 主要结局为基线至产后2周Quick Inventory of Depressive Symptomatology评分变化,连续变量和分类变量(任何症状加重 vs 稳定或改善)分析。
- 次要结局包括基线至产后6周评分变化及产后6周评分升高比例。
临床怎么用
- 对因高血压疾病接受围产期硫酸镁预防子痫的孕妇,可关注其产后早期抑郁症状可能较轻。
- 产后6周仍需常规评估抑郁症状,因硫酸镁与2周症状的关联未持续至6周。
- 目前证据来自观察性研究,不能据此将硫酸镁用于预防产后抑郁。
局限性
- 为前瞻性队列研究,硫酸镁使用非随机化,存在选择偏倚可能。
- 原文未报告样本量计算、失访情况及混杂因素具体列表。
- 抑郁症状评估采用问卷,非临床诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevention of postpartum depression is an important area of investigation given its association with major maternal and neonatal sequelae, yet few evidence-based treatments to reduce the frequency of postpartum depression are used. Recent data suggest that N-methyl-D-aspartate receptor antagonists may lead to rapid improvement of depressive symptoms lasting up to 2 weeks. We hypothesized that the N-methyl-D-aspartate receptor antagonist magnesium sulfate would elicit antidepressant effects subsequent to its receipt by women receiving peripartum seizure prophylaxis for a hypertensive disorder of pregnancy. OBJECTIVE: This study aimed to compare the frequency of depressive symptoms at 2 weeks and 6 weeks after delivery between women who did and did not receive peripartum magnesium sulfate for a hypertensive disorder of pregnancy. STUDY DESIGN: This prospective cohort study included women with a hypertensive disorder of pregnancy at ≥34 weeks' gestation with singleton gestations. Magnesium sulfate for seizure prophylaxis was administered at the obstetrician's discretion. The Quick Inventory of Depressive Symptomatology survey was administered before hospital discharge and again at 2 weeks and 6 weeks after delivery to assess for postpartum depressive symptoms. The primary outcome for this study was the change in Quick Inventory of Depressive Symptomatology score from baseline to 2 weeks after delivery, which was analyzed both continuously and categorically (any symptom worsening vs stability or improvement). Secondary outcomes included the change in Quick Inventory of Depressive Symptomatology score from baseline to 6 weeks after delivery and the proportion of women who experienced an increase in Quick Inventory of Depressive Symptomatology score at 6 weeks after delivery. RESULTS: Of the 342 women enrolled, 39% (n=134) received magnesium sulfate. Compared with women who did not receive magnesium, women who received magnesium had a significantly smaller change in their mean Quick Inventory of Depressive Symptomatology score (0.6±3.4 vs 1.6±3.0; P=.015) and also were less likely to have an increase in Quick Inventory of Depressive Symptomatology score at 2 weeks after delivery (52% vs 67%; P=.022). These differences were not present at 6 weeks after delivery. After controlling for potential confounders, women who received magnesium continued to have a lower odds of having an increased Quick Inventory of Depressive Symptomatology score from baseline at 2 weeks after delivery than women who did not receive magnesium (adjusted odds ratio, 0.88; 95% confidence interval, 0.78-0.98). CONCLUSION: Peripartum magnesium was associated with less of an exacerbation in depressive symptoms in the immediate postpartum period. Given the implications of postpartum depression on maternal and child health and the lack of existing prophylaxis, randomized trials should examine this novel potential prophylactic therapy.
引用
- Miller ES, Sakowicz A, Roy A, et al. Is peripartum magnesium sulfate associated with a reduction in postpartum depressive symptoms? Am J Obstet Gynecol MFM. 2021. PMID: 34058422. doi:10.1016/j.ajogmf.2021.100407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。